A Phase 3 interventional study of tofacitinib and Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 178 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.
Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18+
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18–65
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2008; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 614 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 107 across the 14 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 6th registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
3 of the studies testing tofacitinib in Colitis, Ulcerative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT07297069Asian Institute of Gastroenterology, IndiaCombination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial | 2027-05-31 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing tofacitinib in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have failed or be intolerant of at least one of the following treatments for UC:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tofacitinib
Drug: Placebo
10 mg oral BID
Also known as: CP-690,550
Plabebo oral BID
Percentage of Participants With Remission at Week 8
Remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician global assessment (PGA), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time frame: Week 8
Percentage of Participants Achieving Mucosal Healing at Week 8
Mucosal healing in participants was defined by Mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.
Time frame: Week 8
Percentage of Participants Achieving Clinical Response at Week 8
Clinical response in participants was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time frame: Week 8
Percentage of Participants With Endoscopic Remission at Week 8
Endoscopic remission in participants was defined by Mayo endoscopic subscore of 0. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.
Time frame: Week 8
Percentage of Participants With Clinical Remission at Week 8
Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time frame: Week 8
Percentage of Participants With Symptomatic Remission at Week 8
Symptomatic remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time frame: Week 8
Percentage of Participants With Deep Remission at Week 8
Deep remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time frame: Week 8
Partial Mayo Scores
A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.
Time frame: Baseline, Weeks 2, 4, 8
Change From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8
Change in partial mayo scores at weeks 2, 4, 8 relative to baseline were reported. A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.
Time frame: Baseline, Weeks 2, 4, 8
Change From Baseline in Total Mayo Scores at Week 8
Change in total Mayo scores at Week 8 relative to Baseline was reported. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time frame: Baseline, Week 8
| Milestone | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID | Placebo BID |
|---|---|---|---|
| Started | 476 | 16 | 122 |
| Completed | 445 | 15 | 118 |
| Not completed | 31 | 1 | 4 |
| Withdrew: Withdrawal by subject | 4 | 0 | 1 |
| Withdrew: Insufficient clinical response | 11 | 0 | 1 |
| Withdrew: Adverse event | 9 | 0 | 1 |
| Withdrew: Other | 2 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 1 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
Remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician global assessment (PGA), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
| percentage of participants | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Percentage of Participants With Remission at Week 8 | 18.5 | 8.2 |
Mucosal healing in participants was defined by Mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.
| percentage of participants | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Percentage of Participants Achieving Mucosal Healing at Week 8 | 31.3 | 15.6 |
Clinical response in participants was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
| percentage of participants | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 8 | 59.9 | 32.8 |
Endoscopic remission in participants was defined by Mayo endoscopic subscore of 0. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.
| percentage of participants | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 8 | 6.7 | 1.6 |
Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
| percentage of participants | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 8 | 18.5 | 8.2 |
Symptomatic remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
| percentage of participants | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Percentage of Participants With Symptomatic Remission at Week 8 | 11.8 | 5.7 |
Deep remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
| percentage of participants | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Percentage of Participants With Deep Remission at Week 8 | 6.5 | 0 |
A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.
| units on a scale | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Baseline: (n= 475, 121) | 6.3 ± 1.2 | 6.5 ± 1.2 |
| At Week 2: (n= 465, 122) | 4.2 ± 2.2 | 5.2 ± 2.1 |
| At Week 4: (n= 461, 118) | 3.5 ± 2.3 | 4.8 ± 2.4 |
| At week 8: (n= 449, 119) | 3.2 ± 2.4 | 4.8 ± 2.5 |
Change in partial mayo scores at weeks 2, 4, 8 relative to baseline were reported. A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.
| units on a scale | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Change at Week 2: (n= 464, 121) | -2.1 ± 0.1 | -1.2 ± 0.2 |
| Change at week 4: (n= 460, 117) | -2.8 ± 0.1 | -1.6 ± 0.2 |
| Change at week 8: (n= 448, 118) | -3.1 ± 0.1 | -1.6 ± 0.2 |
Change in total Mayo scores at Week 8 relative to Baseline was reported. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
| units on a scale | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|
| Baseline (n= 472, 121) | 9.0 ± 1.4 | 9.1 ± 1.4 |
| Change at Week 8 (n= 443, 117) | -3.8 ± 2.8 | -1.9 ± 2.5 |
Collected over Baseline up to Day 98. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 10 mg BID | — | 16/476 (3.4%) | 148/476 (31.1%) |
| Tofacitinib 15 mg BID | — | 0/16 (0%) | 12/16 (75%) |
| Placebo BID | — | 5/122 (4.1%) | 38/122 (31.1%) |
| Event | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID | Placebo BID |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 5/476 | 0/16 | 2/122 |
| Animal biteInjury, poisoning and procedural complications | 0/476 | 0/16 | 1/122 |
| Vulva cystReproductive system and breast disorders | 0/476 | 0/16 | 1/122 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/476 | 0/16 | 1/122 |
| Acute coronary syndromeCardiac disorders | 1/476 | 0/16 | 0/122 |
| Intestinal perforationGastrointestinal disorders | 1/476 | 0/16 | 0/122 |
| MalaiseGeneral disorders | 1/476 | 0/16 | 0/122 |
| Drug hypersensitivityImmune system disorders | 1/476 | 0/16 | 0/122 |
| Anal abscessInfections and infestations | 1/476 | 0/16 | 0/122 |
| CellulitisInfections and infestations | 1/476 | 0/16 | 0/122 |
| Event | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID | Placebo BID |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 34/476 | 3/16 | 9/122 |
| AcneSkin and subcutaneous tissue disorders | 10/476 | 3/16 | 0/122 |
| SinusitisInfections and infestations | 2/476 | 2/16 | 1/122 |
| HeadacheNervous system disorders | 37/476 | 0/16 | 8/122 |
| AnaemiaBlood and lymphatic system disorders | 11/476 | 1/16 | 6/122 |
| Colitis ulcerativeGastrointestinal disorders | 6/476 | 1/16 | 3/122 |
| FlatulenceGastrointestinal disorders | 2/476 | 1/16 | 1/122 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/476 | 1/16 | 0/122 |
| NauseaGastrointestinal disorders | 15/476 | 1/16 | 5/122 |
| FatigueGeneral disorders | 10/476 | 1/16 | 4/122 |
The safety analysis set consists of all randomized participants who received at least 1 dose of study medication.
| Age, Customized(participants) | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID | Placebo BID | Total |
|---|---|---|---|---|
| 18 to 44 Years | 295 | 11 | 72 | 378 |
| 45 to 64 Years | 145 | 4 | 39 | 188 |
| Greater Than or Equal to (>=) 65 Years | 36 | 1 | 11 | 48 |
| Sex: Female, Male(Participants) | Tofacitinib 10 mg BID | Tofacitinib 15 mg BID | Placebo BID | Total |
|---|---|---|---|---|
| Female | 199 | 7 | 45 | 251 |
| Male | 277 | 9 | 77 | 363 |
Showing the first 100 of 178 sites across 28 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2012, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib